BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 23770449)

  • 1. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
    Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
    Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel metal complexes of naphthalimide-cyclam conjugates as potential multi-target receptor tyrosine kinase (RTK) inhibitors: synthesis and biological evaluation.
    Tan S; Han K; Li Q; Tong L; Yang Y; Chen Z; Xie H; Ding J; Qian X; Xu Y
    Eur J Med Chem; 2014 Oct; 85():207-14. PubMed ID: 25084146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
    Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
    Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.
    Tomczyk MD; Byczek-Wyrostek A; Strama K; Wawszków M; Kasprzycki P; Walczak KZ
    Med Chem; 2019; 15(5):550-560. PubMed ID: 30207241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of novel C4-benzazole naphthalimide derivatives with potent anti-tumor properties against murine melanoma.
    Lu YT; Chen TL; Chang KS; Chang CM; Wei TY; Liu JW; Hsiao CA; Shih TL
    Bioorg Med Chem; 2017 Jan; 25(2):789-794. PubMed ID: 27939348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.
    Chen Z; Liang X; Zhang H; Xie H; Liu J; Xu Y; Zhu W; Wang Y; Wang X; Tan S; Kuang D; Qian X
    J Med Chem; 2010 Mar; 53(6):2589-600. PubMed ID: 20170164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
    Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
    Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
    Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
    Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation.
    Tan S; Yin H; Chen Z; Qian X; Xu Y
    Eur J Med Chem; 2013 Apr; 62():130-8. PubMed ID: 23353750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
    Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
    Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of naphthalimide-phenanthro[9,10-d]imidazole derivatives: In vitro evaluation, binding interaction with DNA and topoisomerase inhibition.
    Singh I; Luxami V; Paul K
    Bioorg Chem; 2020 Mar; 96():103631. PubMed ID: 32036164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
    Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
    Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
    Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
    Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of 2,4-di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison.
    Karki R; Park C; Jun KY; Kadayat TM; Lee ES; Kwon Y
    Eur J Med Chem; 2015 Jan; 90():360-78. PubMed ID: 25437622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
    Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
    Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA
    Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
    Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
    Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.